NO20034300L - Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer - Google Patents

Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer

Info

Publication number
NO20034300L
NO20034300L NO20034300A NO20034300A NO20034300L NO 20034300 L NO20034300 L NO 20034300L NO 20034300 A NO20034300 A NO 20034300A NO 20034300 A NO20034300 A NO 20034300A NO 20034300 L NO20034300 L NO 20034300L
Authority
NO
Norway
Prior art keywords
diseases
treatment
dihydropyrimidine compounds
substituted dihydropyrimidine
new cyano
Prior art date
Application number
NO20034300A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034300D0 (no
Inventor
Spencer David Kimball
Louis J Lombardo
David B Rawlins
Hai-Yun Xiao
Robert Joseph Schmit
David Kent Williams
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20034300D0 publication Critical patent/NO20034300D0/no
Publication of NO20034300L publication Critical patent/NO20034300L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20034300A 2001-03-29 2003-09-26 Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer NO20034300L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (2)

Publication Number Publication Date
NO20034300D0 NO20034300D0 (no) 2003-09-26
NO20034300L true NO20034300L (no) 2003-11-07

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034300A NO20034300L (no) 2001-03-29 2003-09-26 Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer

Country Status (26)

Country Link
US (1) US6809102B2 (sh)
EP (1) EP1373221A4 (sh)
JP (1) JP2005504725A (sh)
KR (1) KR20030086327A (sh)
CN (1) CN1507435A (sh)
AR (1) AR034585A1 (sh)
BG (1) BG108180A (sh)
BR (1) BR0208405A (sh)
CA (1) CA2442482A1 (sh)
CZ (1) CZ20032645A3 (sh)
EE (1) EE200300474A (sh)
HR (1) HRP20030875A2 (sh)
HU (1) HUP0400350A3 (sh)
IL (1) IL157441A0 (sh)
IS (1) IS6967A (sh)
MX (1) MXPA03008634A (sh)
NO (1) NO20034300L (sh)
PE (1) PE20021013A1 (sh)
PL (1) PL373759A1 (sh)
RU (1) RU2003130961A (sh)
SK (1) SK11062003A3 (sh)
TW (1) TWI228416B (sh)
UY (1) UY27232A1 (sh)
WO (1) WO2002079149A2 (sh)
YU (1) YU75803A (sh)
ZA (2) ZA200306648B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
PT1847534E (pt) * 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
CA2518224C (en) * 2003-03-07 2010-06-15 Astrazeneca Ab Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
CN101787000B (zh) 2003-04-18 2011-08-03 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
EP1773830A1 (en) * 2004-07-22 2007-04-18 AstraZeneca AB Fused pyrimidones useful in the treatment and the prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
KR20070046176A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
WO2006101103A1 (ja) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. 造血器腫瘍治療剤
CA2602397A1 (en) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for solid tumor
US7910611B2 (en) * 2005-06-24 2011-03-22 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for restenosis
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
PL320263A1 (en) 1994-11-16 1997-09-15 Synaptic Pharma Corp Dihydropyrimidines and their application
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1999050440A2 (en) 1998-04-01 1999-10-07 Yale University Method to identify modulators of survivin - tubulin interaction
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
UY27232A1 (es) 2002-11-29
WO2002079149A2 (en) 2002-10-10
WO2002079149A3 (en) 2003-02-27
CZ20032645A3 (cs) 2004-06-16
BR0208405A (pt) 2004-03-30
CA2442482A1 (en) 2002-10-10
KR20030086327A (ko) 2003-11-07
BG108180A (en) 2004-09-30
IL157441A0 (en) 2004-03-28
PE20021013A1 (es) 2002-11-10
US20030008888A1 (en) 2003-01-09
HRP20030875A2 (en) 2004-08-31
EP1373221A2 (en) 2004-01-02
HUP0400350A2 (hu) 2005-01-28
IS6967A (is) 2003-09-24
JP2005504725A (ja) 2005-02-17
SK11062003A3 (sk) 2004-08-03
RU2003130961A (ru) 2005-04-10
NO20034300D0 (no) 2003-09-26
ZA200307320B (en) 2004-12-20
CN1507435A (zh) 2004-06-23
EP1373221A4 (en) 2004-09-29
HUP0400350A3 (en) 2005-06-28
US6809102B2 (en) 2004-10-26
TWI228416B (en) 2005-03-01
EE200300474A (et) 2003-12-15
YU75803A (sh) 2006-05-25
ZA200306648B (en) 2004-11-26
AR034585A1 (es) 2004-03-03
PL373759A1 (en) 2005-09-05
MXPA03008634A (es) 2003-12-08

Similar Documents

Publication Publication Date Title
NO20034300D0 (no) Nye cyano-substituerte dihydropyrimidinforbindelser og anvendelse for behandling av sykdommer
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
IS8135A (is) Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
NO20041272L (no) Tetracycline derivatives and methods of use thereof
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
NO20041024D0 (no) Anvendelse av BIBN4096 i kombinasjon med andre antimigrenelegemidler for behandling av migrene
EE200400074A (et) Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
DK1680405T3 (da) Bengamidderivater og deres anvendelse til behandling af kræftsygdomme
ITPD20030163A1 (it) Impianto per trattamento di materie prime destinate all'impiego nel campo dei ceramici e procedimento per il trattamento di dette materie prime
SE0001569D0 (sv) New compounds and their use in the treatment of alopecia
ITMI20021355A0 (it) Procedimento per il trattamento termico di farine e sfarinati in genere

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application